Business Development

Seeking Partners in Innovation

The Business Development & Strategy group works to commercialize intellectual property generated by Fred Hutch researchers so our discoveries and innovations can contribute to better cancer care at the clinic level. We seek industry partners who share our drive to innovate, collaborate and accelerate development of new inventions and approaches. We also cultivate partnerships with philanthropic supporters, research colleagues and policymakers to extend the reach of our scientific advances.

Our areas of focus include:

  • Blood stem cell transplantation and immunotherapy
  • Cancer risk factors and causes, prevention and treatment outcomes
  • Vaccine development and virus-associated cancers
  • Molecular underpinnings of cancer
  • Tumor-specific translational research
Featured technology

Pretargeted Radioimmunotherapy for Treatment of Multiple Myeloma and B Cell Malignancies

Our researchers have developed antibodies that deliver targeted radioimmunotherapy and avoid systemic toxicity.

Recent Startup Successes

All spinouts & startups
Adaptive Biotechnologies

Adaptive Biotechnologies

Juno Therapeutics, a Bristol Myers Squibb Company

Juno Therapeutics

Faraday Pharmaceuticals

Faraday Pharmaceuticals

Adaptive Biotechnologies

Founded in 2009 by two young Fred Hutch researchers — computational biologist Harlan Robins and molecular biologist and geneticist Chris Carlson — Adaptive Biotechnologies has quickly become a leader in high-throughput DNA sequencing of immune system T cells and B cells for research and diagnostic purposes. In 2018, Adaptive announced a partnership with Microsoft Research to combine its sequencing technology with machine learning and artificial intelligence, with the goal of mapping the entire human immune system and eventually developing a universal blood test to detect any diseases a person’s body may be fighting.

Featured Partnership

LAB591

This collaboration between Fred Hutch and two European partners — Hamburg-based drug discovery and development company Evotec SE and London-based venture capital firm Arix Bioscience — aims to speed up the development of new cancer and infectious disease drugs by providing funding and expertise for the formation of new companies based on discoveries made at Fred Hutch and elsewhere. Launched in 2018, the partnership is administered by the three partner institutions, and all projects are selected by a joint steering committee.

Careers in Business Development

Mailing Address

Fred Hutchinson Cancer Research Center
Business Development
Mail Stop J2-110
PO Box 19024
Seattle, WA 98109-1024

Material transfer agreements or confidential disclosure agreements: MTA@fredhutch.org

Location & Parking

823 Yale Ave. N.
Seattle, WA 98109

Visitors can park in the visitor parking lot adjacent to the Yale Building.

Campus map

Last Modified, July 27, 2021